Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles

Journal of Controlled Release

Volumn 132, Issue 3, 2008, Pages 171-183

  Kratz, Felix ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Albumin nanoparticles; Drug conjugates; Drug delivery; Human serum albumin; Prodrugs

Indexed keywords

ALBUMIN NANOPARTICLES; ANTIVIRAL ACTIVITIES; BIOACTIVE PROTEINS; BREAST CANCERS; CLINICAL SETTINGS; CLINICAL TRIALS; DOXORUBICIN; DRUG CARRIERS; DRUG CONJUGATES; DRUG DELIVERY SYSTEMS; FATTY ACID BINDINGS; FUSION PROTEINS; HEPATITIS C; HUMAN SERUM ALBUMIN; IN PHASE; MYRISTIC ACIDS; PACLITAXEL; PRODRUG; PRODRUGS; SOLID TUMORS; TUMOR TARGETING;

ACIDS; AMINES; ANTIBIOTICS; BINDING ENERGY; BINDING SITES; BIOCHEMISTRY; CIVIL AVIATION; DRUG DELIVERY; FATTY ACIDS; GLYCOPROTEINS; NANOPARTICLES; NANOSTRUCTURES; PROTEINS; TUMORS;

NANOSTRUCTURED MATERIALS;

ALBINTERFERON ALPHA2B; ALBUMIN; CISPLATIN; CJC 1134 PC; CREMOPHOR; DOXORUBICIN; DOXORUBICIN (6 MALEIMIDOCAPROYL)HYDRAZONE; DOXORUBICIN DERIVATIVE; DRUG CARRIER; EXENDIN 4; INNO 206; INSULIN DETEMIR; METHOTREXATE; METHOTREXATE 6 MALEIMIDOCAPROIC ACID DEXTRO ALANYLPHENYLALANYLLYSYLLYSINAMIDE; METHOTREXATE DERIVATIVE; METHOTREXATE HUMAN SERUM ALBUMIN CONJUGATE; MICROSPHERE; NANOPARTICLE; PACLITAXEL; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; BREAST METASTASIS; DIABETES MELLITUS; DIZZINESS; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; HEADACHE; HEPATITIS C; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; LOADING DRUG DOSE; MUCOSA INFLAMMATION; NANOENCAPSULATION; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMATITIS; STRUCTURE ANALYSIS;

ANIMALS; BINDING SITES; BIOLOGICAL TRANSPORT; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DESIGN; DRUG STABILITY; HALF-LIFE; HUMANS; MODELS, MOLECULAR; NANOPARTICLES; PRODRUGS; PROTEIN CONFORMATION; SERUM ALBUMIN;

EID: 56949084877     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.05.010     Document Type: Article

References (101)

1. Peters T. Serum albumin. Adv. Protein Chem. 37 (1985) 161-245
2. Carter D.C., He X.-M., Munson S.H., Twigg P.D., Gernert K.M., Broom M.B., and Miller T.Y. Three-dimensional structure of human serum albumin. Science 244 (1989) 1195-1198
3. Carter D.C., and Ho J.X. Structure of serum albumin. Adv. Protein Chem. 45 (1994) 153-203
4. Fasano M., Curry S., Terreno E., Galliano M., Fanali G., Narciso P., Notari S., and Ascenzi P. The extraordinary ligand binding properties of human serum albumin. IUBMB Life 57 (2005) 787-796
5. Bertucci C., and Domenici E. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr. Med. Chem. 9 (2002) 1463-1481
6. Mendez C.M., McClain C.J., and Marsano L.S. Albumin therapy in clinical practice. Nutr. Clin. Prac. 20 (2005) 314-320
7. Bosse D., Praus M., Kiessling P., Nyman L., Andresen C., Waters J., and Schindel F. Phase I comparability of recombinant human albumin and human serum albumin. J. Clin. Pharmacol. 45 (2005) 57-67
8. Babson A.L., and Winnick T. Protein transfer in tumor-bearing rats. Cancer Res. 14 (1954) 606-611
9. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (1986) 6387-6392
10. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Controlled Release 65 (2000) 271-284
11. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., and Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 4607-4612
12. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756
13. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., and Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89 (1998) 307-314
14. Kratz F., and Beyer U. Serum proteins as drug carriers of anticancer agents: a review. Drug Deliv. 5 (1998) 281-299
15. Stehle G., Sinn H., Wunder A., Schrenk H.H., Stewart J.C., Hartung G., Maier-Borst W., and Heene D.L. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit. Rev. Oncol. 26 (1997) 77-100
16. Wilkinson P., Jeremy R., Brooks F.P., and Hollander J.L. The mechanism of hypoalbuminemia in rheumatoid arthritis. Ann. Intern. Med. 63 (1965) 109-114
17. Ballantyne F.C., Fleck A., and Dick W.C. Albumin metabolism in rheumatoid arthritis. Ann. Rheum. Dis. 30 (1971) 265-270
18. Niwa Y., Iio A., Niwa G., Sakane T., Tsunematsu T., and Kanoh T. Serum albumin metabolism in rheumatic diseases: relationship to corticosteroids and peptic ulcer. J. Clin. Lab. Immunol. 31 (1990) 11-16
19. Levick J.R. Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum. 24 (1981) 1550-1560
20. Wunder A., Muller-Ladner U., Stelzer E.H., Funk J., Neumann E., Stehle G., Pap T., Sinn H., Gay S., and Fiehn C. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J. Immunol. 170 (2003) 4793-4801
21. Wunder A., Muller-Ladner U., Stelzer E.H., Funk J., Neumann E., Stehle G., Pap T., Sinn H., Gay S., and Fiehn C. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J. Immunol. Methods 170 (2003) 4793-4801
22. Subramanian G.M., Fiscella M., Lamouse-Smith A., Zeuzem S., and McHutchison J.G. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol. 25 (2007) 1411-1419
23. Giannoukakis N. CJC-1131. ConjuChem. Curr. Opin. Investig. Drugs 4 (2003) 1245-1249
24. Kurtzhals P. Pharmacology of insulin detemir. Endocrinol. Metab. Clin. North Am. 36 Suppl 1 (2007) 14-20
25. Haag R., and Kratz F. Polymer therapeutics: concepts and applications. Angew. Chem., Int. Ed. Engl. 45 (2006) 1198-1215
26. Kratz F., Mueller-Driver R., Hofmann I., Drevs J., and Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. Chem. 43 (2000) 1253-1256
27. Fiume L., Bolondi L., Busi C., Chieco P., Kratz F., Mattson G., Lanza M., and Di Stefano G. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. J. Hepatol. 43 (2005) 645-652
28. Temming K., Schiffelers R.M., Molema G., and Kok R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist. Update 8 (2005) 381-402
29. Kokudo N., Vera D.R., and Makuuchi M. Clinical application of TcGSA. Nucl. Med. Biol. 30 (2003) 845-849
30. Kremer P., Wunder A., Sinn H., Haase T., Rheinwald M., Zillmann U., Albert F.K., and Kunze S. Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: experimental and preliminary clinical results. Neurol. Res. 22 (2000) 481-489
31. Stehle G., Sinn H., Wunder A., Schrenk H.H., Schutt S., Maier-Borst W., and Heene D.L. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats. Anticancer Drugs 8 (1997) 677-685
32. Stehle G., Wunder A., Sinn H., Schrenk H.H., Schutt S., Frei E., Hartung G., Maier-Borst W., and Heene D.L. Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats. Anticancer Drugs 8 (1997) 835-844
33. Hartung G., Stehle G., Sinn H., Wunder A., Schrenk H.H., S. H., Kränzle L., Fiebig H.H., Maier-Borst W., Heene D.L., and Queißer W. Phase I trial of a methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Clin. Cancer Res. 5 (1999) 753-759
34. Vis A.N., van der Gaast A., van Rhijn B.W., Catsburg T.K., Schmidt C., and Mickisch G.H. A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother. Pharmacol. 49 (2002) 342-345
35. Bolling C., Graefe T., Lubbing C., Jankevicius F., Uktveris S., Cesas A., Meyer-Moldenhauer W.H., Starkmann H., Weigel M., Burk K., and Hanauske A.R. Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest. New Drugs 24 (2006) 521-527
36. Drevs J., Esser N., Richly H., Skorzec M., Scheulen M.E., Unger C., and Kratz F. In vivo efficacy and pharmacokinetic study of an acid-sensitive albumin conjugate in a murine renal cell carcinoma model. Clin. Cancer Res. 6 120 Suppl. (2000)
37. Kratz F., Warnecke A., Scheuermann K., Stockmar C., Schwab J., Lazar P., Drückes P., Esser N., Drevs J., Rognan D., Bissantz C., Hinderling C., Folkers G., Fichtner I., and Unger C. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J. Med. Chem. 45 (2002) 5523-5533
38. Kratz F., Ehling G., Kauffmann H.M., and Unger C. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum. Exp. Toxicol. 26 (2007) 19-35
39. Lebrecht D., Geist A., Ketelsen U.P., Haberstroh J., Setzer B., Kratz F., and Walker U.A. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int. J. Cancer 120 (2007) 927-934
40. Unger C., Haring B., Medinger M., Drevs J., Steinbild S., Kratz F., and Mross K. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin. Cancer Res. 13 (2007) 4858-4866
41. Mansour A.M., Drevs J., Esser N., Hamada F.M., Badary O.A., Unger C., Fichtner I., and Kratz F. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 63 (2003) 4062-4066
42. Schmid B., Chung D.E., Warnecke A., Fichtner I., and Kratz F. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug. Chem. 18 (2007) 702-716
43. Chung D.E., and Kratz F. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA). Bioorg. Med. Chem. Lett. 16 (2006) 5157-5163
44. Kratz F., Mansour A., Soltau J., Warnecke A., Fichtner I., Unger C., and Drevs J. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen (PSA). Arch. Pharm. 338 (2005) 462-472
45. Graeser R., Chung D.E., Esser N., Moor S., Schachtele C., Unger C., and Kratz F. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP). Int. J. Cancer 122 (2008) 1145-1154
46. Warnecke A., Fichtner I., Sass G., and Kratz F. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch. Pharm. (Weinheim) 340 (2007) 389-395
47. Schmid B., Warnecke A., Fichtner I., Jung M., and Kratz F. Development of albumin-binding camptothecin prodrugs using a peptide positional scanning library. Bioconjug. Chem. 18 (2007) 1786-1799
48. Warnecke A., and Kratz F. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy. Bioconjug. Chem. 14 (2003) 377-387
49. Beyer U., Schumacher P., Unger C., Frahm A.W., and Kratz F. Synthesis of maleimide derivatives of the anticancer drugs 5-fluorouracil and 5′-deoxy-5-fluorouridine for the preparation of chemoimmunoconjugates. Pharmazie 52 (1996) 480-482
50. Warnecke A., Fichtner I., Garmann D., Jaehde U., and Kratz F. Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs. Bioconjug. Chem. 15 (2004) 1349-1359
51. Fiehn C., Muller-Ladner U., Gay S., Krienke S., Freudenberg-Konrad S., Funk J., Ho A.D., Sinn H., and Wunder A. Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatology (Oxford) 43 (2004) 1097-1105
52. Fiehn C., Neumann E., Wunder A., Krienke S., Gay S., and Muller-Ladner U. Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo. Ann. Rheum. Dis. 63 (2004) 884-886
53. Ikeda Y., Ikata T., Mishiro T., Nakano S., Ikebe M., and Yasuoka S. Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase. J. Med. Invest. 47 (2000) 61-75
54. Fiume L., Di Stefano G., Busi C., Mattioli A., Bonino F., Torrani-Cerenzia M., Verme G., Rapicetta M., Bertini M., and Gervasi G.B. Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor. J. Viral. Hepat. 4 (1997) 363-370
55. Di Stefano G., Kratz F., Lanza M., and Fiume L. Doxorubicin coupled to lactosaminated human albumin remains confined within mouse liver cells after the intracellular release from the carrier. Digestive and Liver Disease 35 (2003) 428-433
56. Di Stefano G., Derenzini M., Kratz F., Lanza M., and Fiume L. Liver-targeted doxorubicin: effects on rat regenerating hepatocytes. Liver International 24 (2004) 246-252
57. Fiume L., Bolondi L., Busi C., Chieco P., Kratz F., Lanza M., Mattioli A., and Di Stefano G. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. J. Hepatol. 43 (2005) 645-652
58. Trerè D., Fiume L., Badiali De Giorgi L., Di Stefano G., Migaldi M., and Derenzini M. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. Br. J. Cancer 81 (1999) 404-408
59. Kratz F. Drug conjugates with albumin and transferrin. Exp. Opin. Ther. Pat. 12 (2002) 433-439
60. Holmes D.L., Thibaudeau K., L'Archeveque B., Milner P.G., Ezrin A.M., and Bridon D.P. Site specific 1:1 opioid:albumin conjugate with in vitro activity and long in vivo duration. Bioconjug. Chem. 11 (2000) 439-444
61. Drucker D.J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 17 (2003) 161-171
62. Kim J.G., Baggio L.L., Bridon D.P., Castaigne J.P., Robitaille M.F., Jette L., Benquet C., and Drucker D.J. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52 (2003) 751-759
63. Kurtzhals P., Havelund S., Jonassen I., and Markussen J. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J. Pharm. Sci. 86 (1997) 1365-1368
64. Home P., and Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin. Pharmacother. 7 (2006) 325-343
65. Chemmanur A.T., and Wu G.Y. Drug evaluation: albuferon-alpha-an antiviral interferon-alpha/albumin fusion protein. Curr. Opin. Investig. Drugs 7 (2006) 750-758
66. Melder R.J., Osborn B.L., Riccobene T., Kanakaraj P., Wei P., Chen G., Stolow D., Halpern W.G., Migone T.S., Wang Q., Grzegorzewski K.J., and Gallant G. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol. Immunothe.r 54 (2005) 535-547
67. Gupta P.K., and Hung C.T. Albumin microspheres. II: Applications in drug delivery. J. Microencapsul 6 (1989) 463-472
68. Gupta P.K., and Hung C.T. Albumin microspheres. I: Physico-chemical characteristics. J. Microencapsul 6 (1989) 427-462
69. Weiss M., Gildehaus F.J., Brinkbaumer K., Makowski M., and Hahn K. Lymph kinetics with technetium-99 m labeled radiopharmaceuticals. Animal studies. Nuklearmedizin 44 (2005) 156-165
70. Jimenez I.R., Roca M., Vega E., Garcia M.L., Benitez A., Bajen M., and Martin-Comin J. Particle size of colloids to be used in sentinel lymph node radiolocalization. Nucl. Med. Commun. 29 (2008) 166-172
71. Nishiyama Y., Yamamoto Y., Mori Y., Satoh K., Takashima H., Ohkawa M., and Tanabe M. Usefulness of Technetium-99 m human serum albumin lymphoscintigraphy in chyluria. Clin. Nucl. Med. 23 (1998) 429-431
72. Rink T., Heuser T., Fitz H., Schroth H.J., Weller E., and Zippel H.H. Lymphoscintigraphic sentinel node imaging and gamma probe detection in breast cancer with Tc-99 m nanocolloidal albumin: results of an optimized protocol. Clin. Nucl. Med. 26 (2001) 293-298
73. Bedrosian I., Scheff A.M., Mick R., Callans L.S., Bucky L.P., Spitz F.R., Helsabeck C., Elder D.E., Alavi A., Fraker D.F., and Czerniecki B.J. 99mTc-human serum albumin: an effective radiotracer for identifying sentinel lymph nodes in melanoma. J. Nucl. Med. 40 (1999) 1143-1148
74. Dhabuwala A., Lamerton P., and Stubbs R.S. Relationship of 99mtechnetium labelled macroaggregated albumin (99mTc-MAA) uptake by colorectal liver metastases to response following selective internal radiation therapy (SIRT). BMC Nuclear Medicine 5 (2005) 7
75. Suga K., Kume N., Matsunaga N., Motoyama K., Hara A., and Ogasawara N. Assessment of leg oedema by dynamic lymphoscintigraphy with intradermal injection of technetium-99 m human serum albumin and load produced by standing. Eur. J. Nucl. Med. 28 (2001) 294-303
76. Chiu N.T., Lee B.F., Hwang S.J., Chang J.M., Liu G.C., and Yu H.S. Protein-losing enteropathy: diagnosis with (99 m)Tc-labeled human serum albumin scintigraphy. Radiology 219 (2001) 86-90
77. Adams B.K., Al Attia H.M., Khadim R.A., and Al Haider Z.Y. 99Tc(m) nanocolloid scintigraphy: a reliable way to detect active joint disease in patients with peripheral joint pain. Nucl. Med. Commun. 22 (2001) 315-318
78. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., Tao C., De T., Beals B., Dykes D., Noker P., Yao R., Labao E., Hawkins M., and Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12 (2006) 1317-1324
79. John T.A., Vogel S.M., Tiruppathi C., Malik A.B., and Minshall R.D. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am. J. Physiol. Lung Cell Mol. Physiol. 284 (2003) L187-196
80. Porter P.L., Sage E.H., Lane T.F., Funk S.E., and Gown A.M. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem. 43 (1995) 791-800
81. Goble S., and Bear H.D. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg. Clin. North Am. 83 (2003) 943-971
82. Gelderblom H., Verweij J., Nooter K., Sparreboom A., and Cremophor E.L. The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37 (2001) 1590-1598
83. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., Esmaeli B., Ring S.E., Bedikian A., Hortobagyi G.N., and Ellerhorst J.A. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8 (2002) 1038-1044
84. Ibrahim N.K., Samuels B., Page R., Doval D., Patel K.M., Rao S.C., Nair M.K., Bhar P., Desai N., and Hortobagyi G.N. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol. 23 (2005) 6019-6026
85. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., and O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23 (2005) 7794-7803
86. Guan Z., Feng F., Li Q.L., Jiang Z., Shen Z., Yu S., Feng J., Huang J., Yao Z., and Hawkins M.J. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J. Clin. Oncol. 25 (2007) 1038
87. Anatelli F., Mroz P., Liu Q., Yang C., Castano A.P., Swietlik E., and Hamblin M.R. Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection. Mol. Pharm. 3 (2006) 654-664
88. Brasseur N., Langlois R., La Madeleine C., Ouellet R., and van Lier J.E. Receptor-mediated targeting of phthalocyanines to macrophages via covalent coupling to native or maleylated bovine serum albumin. Photochem. Photobiol. 69 (1999) 345-352
89. Kratz F. Interactions of antitumour metal complexes with serum proteins. Perspectives for anticancer drug development. A review. In: Keppler B.K. (Ed). Metal Complexes as Antitumour Agents (1993), Verlag Chemie, Weinheim
90. Kratz F., and Schütte M.T. Anticancer metal complexes and tumour targeting strategies. Cancer J. 11 (1998) 60-67
91. Swart P.J., Beljaars L., Kuipers M.E., Smit C., Nieuwenhuis P., and Meijer D.K. Homing of negatively charged albumins to the lymphatic system: general implications for drug targeting to peripheral tissues and viral reservoirs. Biochem. Pharmacol. 58 (1999) 1425-1435
92. Kuipers M.E., Swart P.J., Witvrouw M., Este J.A., Reymen D., De Clercq E., and Meijer D.K. Anti-HIV-1 activity of combinations and covalent conjugates of negatively charged human serum albumins (NCAs) and AZT. J. Drug. Targeting 6 (1999) 323-335
93. Kuipers M.E., vd Berg M., Swart P.J., Laman J.D., Meijer D.K., Koppelman M.H., and Huisman H. Mechanism of anti-HIV activity of succinylated human serum albumin. Biochem. Pharmacol. 57 (1999) 889-898
94. Bickel U., Yoshikawa T., and Pardridge W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 46 (2001) 247-279
95. Pardridge W.M., Triguero D., and Buciak J.L. Beta-endorphin chimeric peptides: transport through the blood-brain barrier in vivo and cleavage of disulfide linkage by brain. Endocrinology 126 (1990) 977-984
96. Mo Y., Barnett M.E., Takemoto D., Davidson H., and Kompella U.B. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol. Vis. 13 (2007) 746-757
97. Fischer D., Bieber T., Brusselbach S., Elsasser H., and Kissel T. Cationized human serum albumin as a non-viral vector system for gene delivery? Characterization of complex formation with plasmid DNA and transfection efficiency. Int. J. Pharm. 225 (2001) 97-111
98. Shohet R.V., Chen S., Zhou Y.T., Wang Z., Meidell R.S., Unger R.H., and Grayburn P.A. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation 101 (2000) 2554-2556
99. Komatsu T., Oguro Y., Nakagawa A., and Tsuchida E. Albumin clusters: structurally defined protein tetramer and oxygen carrier including thirty-two iron(II) porphyrins. Biomacromolecules 6 (2005) 3397-3403
100. Nakagawa A., Komatsu T., Iizuka M., and Tsuchida E. Human serum albumin hybrid incorporating tailed porphyrinatoiron(II) in the alpha,alpha,alpha,beta-conformer as an O2-binding site. Bioconjug. Chem. 17 (2006) 146-151
101. Kratz F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin. Investig. Drugs 16 (2007) 855-866